metformin has been researched along with Cardiac Diseases in 28 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We herein report a case of cardiac dysfunction due to thiamine deficiency after hemodialysis in a patient with suspected biguanide-related lactic acidosis." | 8.12 | Cardiac Dysfunction Due to Thiamine Deficiency after Hemodialysis for Biguanide-related Lactic Acidosis. ( Jimura, F; Kachi, N; Tamaki, H; Tsushima, H, 2022) |
| "Insulin resistance has been shown to be associated with cardiac sympathovagal imbalance, myocardial dysfunction, and cardiac mitochondrial dysfunction." | 5.38 | Cardioprotective effects of metformin and vildagliptin in adult rats with insulin resistance induced by a high-fat diet. ( Apaijai, N; Chattipakorn, N; Chattipakorn, SC; Pintana, H, 2012) |
| "Metformin is a widely used antidiabetic agent that is generally considered safe." | 5.37 | Metformin-associated lactic acidosis in Chinese patients with type II diabetes. ( Chan, WM; Chung, HY; Fong, BM; Siu, TS; Tam, S; Tsai, NW; Tsui, SH; Yeung, CW, 2011) |
| "There is no evidence that the use of contrast media (CM) in diabetic patients with serum creatinine <130 μmole/L leads to metformin accumulation and subsequent lactic acidosis." | 5.15 | Monitoring metformin in cardiac patients exposed to contrast media using ultra-high-performance liquid chromatography tandem mass-spectrometry. ( Al Babtain, MA; Al Taweel, ES; Al-Amri, HS; Al-Moghairi, AM; Aloudah, NM; Radwan, MA, 2011) |
| " We herein report a case of cardiac dysfunction due to thiamine deficiency after hemodialysis in a patient with suspected biguanide-related lactic acidosis." | 4.12 | Cardiac Dysfunction Due to Thiamine Deficiency after Hemodialysis for Biguanide-related Lactic Acidosis. ( Jimura, F; Kachi, N; Tamaki, H; Tsushima, H, 2022) |
| "In patients with diabetes mellitus, subclinical LV dysfunction is common and associated with poor diabetic control, advancing age, hypertension and metformin treatment; ACE inhibitor and insulin therapies appear to be protective." | 3.73 | Determinants of subclinical diabetic heart disease. ( Downey, M; Fang, ZY; Marwick, TH; Prins, J; Schull-Meade, R, 2005) |
| " This is largely due to the historical experience of lactic acidosis with phenformin, despite the fact that metformin does not predispose to this when compared with other therapies." | 3.73 | Contraindications can damage your health--is metformin a case in point? ( Holstein, A; Stumvoll, M, 2005) |
| "Recent data suggest that type 2 diabetes patients who are considered as being "at risk" because of the presence of cardiac disease still take benefit from metformin therapy, with a reduction of morbidity and mortality compared with other glucose-lowering agents." | 2.49 | [Use of metformin in diabetic patients with cardiac disease: benefit-risk balance]. ( Paquot, N; Scheen, AJ, 2013) |
| "Early type 2 diabetes mellitus (DM) may only require lifestyle modifications for glycemic control without the need for oral hypoglycemic agents (OHAs)." | 1.46 | Metformin is associated with fewer major adverse cardiac events among patients with a new diagnosis of type 2 diabetes mellitus: A propensity score-matched nationwide study. ( Chang, SH; Kuo, CT; Lee, CH; Lee, KT; Liu, JR; See, LC; Wen, MS; Wu, LS; Yeh, YH, 2017) |
| "Pretreatment with metformin normalized the levels of all these factors." | 1.43 | Metformin protects against infection-induced myocardial dysfunction. ( Cokkinos, DV; Kapelouzou, A; Karalis, KP; Kontaridis, MI; Ninou, E; Theocharis, S; Tzanavari, T; Varela, A, 2016) |
| "From the 479 patients with NAFLD assessed, 302 patients (63%) greater than 18 years old were included." | 1.39 | NAFLD fibrosis score: a prognostic predictor for mortality and liver complications among NAFLD patients. ( Björnsson, E; Enders, F; Lindor, KD; Suwanwalaikorn, S; Treeprasertsuk, S, 2013) |
| "Insulin resistance has been shown to be associated with cardiac sympathovagal imbalance, myocardial dysfunction, and cardiac mitochondrial dysfunction." | 1.38 | Cardioprotective effects of metformin and vildagliptin in adult rats with insulin resistance induced by a high-fat diet. ( Apaijai, N; Chattipakorn, N; Chattipakorn, SC; Pintana, H, 2012) |
| "Metformin is a widely used antidiabetic agent that is generally considered safe." | 1.37 | Metformin-associated lactic acidosis in Chinese patients with type II diabetes. ( Chan, WM; Chung, HY; Fong, BM; Siu, TS; Tam, S; Tsai, NW; Tsui, SH; Yeung, CW, 2011) |
| "Treatment with rosiglitazone enhanced glucose utilization and diminished MFAO, thus reversing the metabolic phenotype of the diabetic heart." | 1.35 | In vivo metabolic phenotyping of myocardial substrate metabolism in rodents: differential efficacy of metformin and rosiglitazone monotherapy. ( Finck, BN; Gropler, RJ; Herrero, P; Schechtman, KB; Sharp, T; Shoghi, KI; Welch, MJ, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (3.57) | 18.7374 |
| 1990's | 2 (7.14) | 18.2507 |
| 2000's | 6 (21.43) | 29.6817 |
| 2010's | 14 (50.00) | 24.3611 |
| 2020's | 5 (17.86) | 2.80 |
| Authors | Studies |
|---|---|
| Luan, Y | 2 |
| Feng, Q | 1 |
| Chen, X | 1 |
| Ren, KD | 1 |
| Yang, Y | 1 |
| Tamaki, H | 1 |
| Tsushima, H | 1 |
| Kachi, N | 1 |
| Jimura, F | 1 |
| Gao, J | 1 |
| Yuan, J | 1 |
| Wang, Q | 1 |
| Lei, T | 1 |
| Shen, X | 1 |
| Cui, B | 1 |
| Zhang, F | 1 |
| Ding, W | 1 |
| Lu, Z | 1 |
| Ajzashokouhi, AH | 1 |
| Bostan, HB | 1 |
| Jomezadeh, V | 1 |
| Hayes, AW | 1 |
| Karimi, G | 1 |
| Timm, KN | 1 |
| Tyler, DJ | 1 |
| Lee, KT | 1 |
| Yeh, YH | 1 |
| Chang, SH | 1 |
| See, LC | 1 |
| Lee, CH | 1 |
| Wu, LS | 1 |
| Liu, JR | 1 |
| Kuo, CT | 1 |
| Wen, MS | 1 |
| Scheen, AJ | 2 |
| Lefèbvre, PJ | 1 |
| Paquot, N | 2 |
| Treeprasertsuk, S | 1 |
| Björnsson, E | 1 |
| Enders, F | 1 |
| Suwanwalaikorn, S | 1 |
| Lindor, KD | 1 |
| Cai, H | 1 |
| Zhang, G | 1 |
| Chen, W | 1 |
| Zhang, B | 1 |
| Zhang, J | 1 |
| Chang, J | 1 |
| Tang, C | 1 |
| Qi, Y | 1 |
| Yin, X | 1 |
| Curry, A | 1 |
| Check Hayden, E | 1 |
| Tzanavari, T | 1 |
| Varela, A | 1 |
| Theocharis, S | 1 |
| Ninou, E | 1 |
| Kapelouzou, A | 1 |
| Cokkinos, DV | 1 |
| Kontaridis, MI | 1 |
| Karalis, KP | 1 |
| Shoghi, KI | 1 |
| Finck, BN | 1 |
| Schechtman, KB | 1 |
| Sharp, T | 1 |
| Herrero, P | 1 |
| Gropler, RJ | 1 |
| Welch, MJ | 1 |
| Monte, SV | 1 |
| Schentag, JJ | 1 |
| Adelman, MH | 1 |
| Paladino, JA | 1 |
| Yeung, CW | 1 |
| Chung, HY | 1 |
| Fong, BM | 1 |
| Tsai, NW | 1 |
| Chan, WM | 1 |
| Siu, TS | 1 |
| Tam, S | 1 |
| Tsui, SH | 1 |
| Radwan, MA | 1 |
| Al Taweel, ES | 1 |
| Al-Moghairi, AM | 1 |
| Aloudah, NM | 1 |
| Al Babtain, MA | 1 |
| Al-Amri, HS | 1 |
| Quentin, T | 1 |
| Steinmetz, M | 1 |
| Poppe, A | 1 |
| Thoms, S | 1 |
| Apaijai, N | 1 |
| Pintana, H | 1 |
| Chattipakorn, SC | 1 |
| Chattipakorn, N | 1 |
| Aragno, M | 1 |
| Mastrocola, R | 1 |
| Ghé, C | 1 |
| Arnoletti, E | 1 |
| Bassino, E | 1 |
| Alloatti, G | 1 |
| Muccioli, G | 1 |
| Stiefelhagen, P | 1 |
| Fang, ZY | 1 |
| Schull-Meade, R | 1 |
| Downey, M | 1 |
| Prins, J | 1 |
| Marwick, TH | 1 |
| Holstein, A | 2 |
| Stumvoll, M | 1 |
| Schnell, O | 1 |
| Nightingale, SL | 1 |
| Nahrwold, D | 1 |
| Hinze, S | 1 |
| Egberts, EH | 1 |
| Duwoos, H | 1 |
| Bertrand, CM | 1 |
| Husson, A | 1 |
| Cramer, J | 1 |
| Tayot, J | 1 |
4 reviews available for metformin and Cardiac Diseases
| Article | Year |
|---|---|
Emerging Role of Mitophagy in the Heart: Therapeutic Potentials to Modulate Mitophagy in Cardiac Diseases.
Topics: Diabetic Cardiomyopathies; Heart Diseases; Humans; Metformin; MicroRNAs; Microtubule-Associated Prot | 2021 |
A review on the cardioprotective mechanisms of metformin against doxorubicin.
Topics: Antibiotics, Antineoplastic; Doxorubicin; Heart Diseases; Humans; Hypoglycemic Agents; Metformin | 2020 |
The Role of AMPK Activation for Cardioprotection in Doxorubicin-Induced Cardiotoxicity.
Topics: Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Animals; Antibiotics, Antineoplastic; Cal | 2020 |
[Use of metformin in diabetic patients with cardiac disease: benefit-risk balance].
Topics: Diabetes Mellitus, Type 2; Heart Diseases; Humans; Hypoglycemic Agents; Metformin; Risk Assessment | 2013 |
1 trial available for metformin and Cardiac Diseases
| Article | Year |
|---|---|
Monitoring metformin in cardiac patients exposed to contrast media using ultra-high-performance liquid chromatography tandem mass-spectrometry.
Topics: Acidosis, Lactic; Cardiac Catheterization; Chromatography, High Pressure Liquid; Contrast Media; Cre | 2011 |
23 other studies available for metformin and Cardiac Diseases
| Article | Year |
|---|---|
Cardiac Dysfunction Due to Thiamine Deficiency after Hemodialysis for Biguanide-related Lactic Acidosis.
Topics: Acidosis, Lactic; Beriberi; Biguanides; Diabetes Mellitus, Type 2; Heart Diseases; Humans; Hypoglyce | 2022 |
Metformin protects against PM
Topics: AMP-Activated Protein Kinases; Animals; Biomarkers; Biopsy; Cell Line; Disease Models, Animal; Disea | 2020 |
Metformin is associated with fewer major adverse cardiac events among patients with a new diagnosis of type 2 diabetes mellitus: A propensity score-matched nationwide study.
Topics: Adolescent; Adult; Aged; Comorbidity; Databases, Factual; Diabetes Mellitus, Type 2; Female; Follow- | 2017 |
[Reappraisal of metformin : less restrictions and more potential indications].
Topics: Contraindications, Drug; Diabetes Mellitus, Type 2; Heart Diseases; Humans; Hypoglycemic Agents; Met | 2018 |
NAFLD fibrosis score: a prognostic predictor for mortality and liver complications among NAFLD patients.
Topics: Adult; Aged; Aged, 80 and over; Biopsy; Cause of Death; Chi-Square Distribution; Decision Support Te | 2013 |
Metformin protects the myocardium against isoproterenol-induced injury in rats through alleviating endoplasmic reticulum stress.
Topics: Adrenergic beta-Agonists; AMP-Activated Protein Kinases; Animals; Apoptosis; Blotting, Western; Card | 2014 |
Young at heart. Could metformin help type 1 teens avoid heart disease as adults?
Topics: Adolescent; Adult; Diabetes Mellitus, Type 1; Heart Diseases; Humans; Hypoglycemic Agents; Metformin | 2014 |
Anti-ageing pill pushed as bona fide drug.
Topics: Aging; Animals; Caloric Restriction; Clinical Trials as Topic; Cognition Disorders; Diabetes Mellitu | 2015 |
Metformin protects against infection-induced myocardial dysfunction.
Topics: Adenosine Triphosphate; Animals; Autophagy; Cardiomyopathies; Echocardiography; Fatty Acids; Glucose | 2016 |
In vivo metabolic phenotyping of myocardial substrate metabolism in rodents: differential efficacy of metformin and rosiglitazone monotherapy.
Topics: Animals; Biological Transport; Diabetes Mellitus, Type 2; Disease Models, Animal; Echocardiography; | 2009 |
Glucose supply and insulin demand dynamics of antidiabetic agents.
Topics: 1-Deoxynojirimycin; Acarbose; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus, Ty | 2010 |
Metformin-associated lactic acidosis in Chinese patients with type II diabetes.
Topics: Acidosis, Lactic; Adult; Aged; Aged, 80 and over; Amylases; Asian People; China; Creatinine; Diabete | 2011 |
Metformin differentially activates ER stress signaling pathways without inducing apoptosis.
Topics: Activating Transcription Factor 4; Animals; Apoptosis; Cardiotonic Agents; Cells, Cultured; Diabetes | 2012 |
Cardioprotective effects of metformin and vildagliptin in adult rats with insulin resistance induced by a high-fat diet.
Topics: Adamantane; Animals; Blood Glucose; Body Weight; Diet, High-Fat; Dipeptidyl-Peptidase IV Inhibitors; | 2012 |
Obestatin induced recovery of myocardial dysfunction in type 1 diabetic rats: underlying mechanisms.
Topics: AMP-Activated Protein Kinases; Animals; Blotting, Western; Cardiotonic Agents; Cell Line; Diabetes M | 2012 |
[Stroke is not equal to stroke. Keep track of the causes].
Topics: Adult; Antihypertensive Agents; Aspirin; Carotid Artery, Common; Carotid Artery, External; Carotid S | 2003 |
Determinants of subclinical diabetic heart disease.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Blood Glucose; Body Mass Index; Diabetes Complicati | 2005 |
Contraindications can damage your health--is metformin a case in point?
Topics: Acidosis, Lactic; Aging; Contraindications; Diabetes Mellitus, Type 2; Heart Diseases; Humans; Hypog | 2005 |
[Glucose control in cardiac disease].
Topics: Acarbose; Blood Glucose; Controlled Clinical Trials as Topic; Diabetes Complications; Glucose; Gluco | 2006 |
New medications help those with diabetes avoid heart trouble. Drugs mimic the body's natural insulin and glucose controls, but diet and exercise are still keys to controlling the disease.
Topics: Diabetes Mellitus; Diabetic Angiopathies; Exenatide; Heart Diseases; Humans; Hypoglycemic Agents; Me | 2007 |
From the Food and Drug Administration.
Topics: Aspirin; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Labeling; Drugs, Investigational; | 1993 |
Contra-indications to metformin therapy are largely disregarded.
Topics: Adult; Aged; Aged, 80 and over; Contraindications; Coronary Disease; Cross-Sectional Studies; Diabet | 1999 |
[Reversible hyperlactatemia induced by phenformin with muscular asthenia and cardio-respiratory signs].
Topics: Aged; Animals; Asthenia; Diabetes Complications; Diabetic Ketoacidosis; Dyspnea; Heart Diseases; Hep | 1970 |